<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">Tumor lysis syndrome</z:e> and <z:hpo ids='HP_0000083'>renal failure</z:hpo> remain important complications early in the course of therapy for pediatric Non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), frequently leading to therapeutic alterations </plain></SENT>
<SENT sid="1" pm="."><plain>In the presented series, children with NHL and <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> are retrospectively analysed regarding clinical features of <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> and its implications on therapy </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: From 4/1990 to 10/1997, 1192 patients diagnosed of any form of NHL have been registered in the NHL-BFM trials </plain></SENT>
<SENT sid="3" pm="."><plain>63 of these patients were reported to have suffered from <z:hpo ids='HP_0000082'>impaired renal function</z:hpo> and/or <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> before or during initial treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical data of these patients were analysed regarding diagnosis, stage, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass, therapy and complications </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: 62 of 63 patients with <z:hpo ids='HP_0000082'>impaired renal function</z:hpo> and/or <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> were diagnosed of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>; 58 (92%) of these patients had advanced stages of disease and high LDH-levels (&gt; 500 U/l) </plain></SENT>
<SENT sid="6" pm="."><plain>43 of 63 patients had already signs of <z:hpo ids='HP_0000082'>impaired renal function</z:hpo> at admission </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002149'>Hyperuricemia</z:hpo> was the commonest cause of <z:hpo ids='HP_0000082'>impaired renal function</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Renal infiltration or enlargement was observed in 27 of 63 patients </plain></SENT>
<SENT sid="9" pm="."><plain>6 patients were diagnosed of <z:e sem="disease" ids="C0178879" disease_type="Disease or Syndrome" abbrv="">urinary tract obstruction</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>25 patients required hemodialysis </plain></SENT>
<SENT sid="11" pm="."><plain>Despite improved renal function before administration of MTX, 21 of 63 patients suffered from protracted MTX-elimination during the first course of therapy </plain></SENT>
<SENT sid="12" pm="."><plain>7 of 63 patients (11%) with <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> died of <z:hpo ids='HP_0100806'>sepsis</z:hpo> after the first course of therapy, another two patients died within 48 hours of therapy due to <z:e sem="disease" ids="C0852198,C0342579" disease_type="Pathologic Function;Disease or Syndrome" abbrv="">electrolyte imbalances</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: In <z:e sem="disease" ids="C0220612" disease_type="Neoplastic Process" abbrv="">pediatric NHL</z:e>-patients, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> appear to be the commonest cause of metabolic complications early in chemotherapy </plain></SENT>
<SENT sid="14" pm="."><plain>Patients with advanced stages and large <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass are at high risk for <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain><z:hpo ids='HP_0000082'>Impaired renal function</z:hpo> predisposes patients to further complications and toxic <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>Prophylactic use of urate-oxidase in <z:hpo ids='HP_0000001'>all</z:hpo> patients with advanced stage NHL might limit the incidence of <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> </plain></SENT>
<SENT sid="17" pm="."><plain>Prospective studies on renal function prior to and during therapy are required in order to develop a clinical profile reliably detecting patients at risk for developing <z:hpo ids='HP_0000083'>renal failure</z:hpo> and subsequent complications </plain></SENT>
</text></document>